Pfizer Inc. has agreed to buy Hospira Inc. in a $16 billion, all-cash deal that would expand the New York pharmaceutical company’s sales of injectable drugs and lower-priced, copycat versions of expensive biotech drugs, the Wall Street Journal reports. Hospira, based in Lake Forest, Ill., is among the leading companies selling injectable drugs and copycat drugs, known as biosimilars.